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PURPOSE. Three congenital fibrosis of the extraocular muscles
phenotypes (CFEOM1–3) have been identified. Each repre-
sents a specific form of paralytic strabismus characterized by
congenital restrictive ophthalmoplegia, often with accompany-
ing ptosis. It has been demonstrated that CFEOM1 results from
mutations in KIF21A and CFEOM2 from mutations in
PHOX2A. This study was conducted to determine the inci-
dence of KIF21A and PHOX2A mutations among individuals
with the third CFEOM phenotype, CFEOM3.
METHODS. All pedigrees and sporadic individuals with CFEOM3
in the authors’ database were identified, whether the pedigrees
were linked or consistent with linkage to the FEOM1, FEOM2,
and/or FEOM3 loci was determined, and the appropriate ped-
igrees and the sporadic individuals were screened for muta-
tions in KIF21A and PHOX2A.
RESULTS. Twelve CFEOM3 pedigrees and 10 CFEOM3 sporadic
individuals were identified in the database. The structures of
eight of the pedigrees permitted the generation of meaningful
linkage data. KIF21A was screened in 17 probands, and muta-
tions were identified in two CFEOM3 pedigrees. One pedigree
harbored a novel mutation (2841G3A, M947I) and one har-
bored the most common and recurrent of the CFEOM1 muta-
tions identified previously (2860C3T, R954W). None of
CFEOM3 pedigrees or sporadic individuals harbored mutations
in PHOX2A.
CONCLUSIONS. The results demonstrate that KIF21A mutations
are a rare cause of CFEOM3 and that KIF21A mutations can be
nonpenetrant. Although KIF21A is the first gene to be associ-
ated with CFEOM3, the results imply that mutations in the
unidentified FEOM3 gene are the more common cause of this
phenotype. (Invest Ophthalmol Vis Sci. 2004;45:2218–2223)
DOI:10.1167/iovs.03-1413
We have defined three congenital fibrosis of the extraoc-ular muscles phenotypes, CFEOM1–3. In each, affected
individuals are born with a nonprogressive ophthalmoplegia
affecting extraocular muscles primarily in the oculomotor
and/or trochlear nerve distribution. We group these three
syndromes with the various forms of Duane syndrome, con-
genital ptosis, congenital facial palsy, and Moebius syndrome as
the congenital cranial dysinnervation disorders (CCDDs), a
term we recently proposed for disorders we believe result
from aberrant innervation of the ocular and facial muscula-
ture.1
Individuals with CFEOM1 (OMIM 135700; http://www.
ncbi.nlm.nih.gov/Omim/, provided in the public domain by
the National Center for Biotechnology Information, Bethesda,
MD) are born with bilateral ophthalmoplegia and ptosis, with
the primary globe position of each eye infraducted (down-
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ward) and with the inability to raise either above the horizontal
midline. The phenotype is quite stereotypic and varies among
affected individuals only in the degree of residual normal and
aberrant movement within the lower quadrants. Our neuro-
pathologic study demonstrated that CFEOM1 results from ab-
sence or hypoplasia of the superior division of the oculomotor
nerve and corresponding -motoneurons in the midbrain, with
hypoplasia of the levator palpebrae superioris and superior
rectus muscles and, presumably, aberrant innervation of other
extraocular muscles.2 CFEOM1 is the most common of the
CFEOM phenotypes and is inherited as a fully penetrant auto-
somal dominant trait. We have demonstrated that in most
pedigrees CFEOM1 maps to the FEOM1 locus on chromosome
12cen,3–6 and results from recurrent heterozygous mutations
in a developmental kinesin, KIF21A.7 Similar to other members
of the kinesin superfamily, mouse Kif21a is a motor protein
engaged in anterograde axonal transport.8 We have identified
six different pathogenic KIF21A mutations in 44 (98%) of 45
CFEOM1 probands. The KIF21A mutations found in CFEOM1
preferentially alter several conserved amino acid residues
within the KIF21A stalk region, and we propose they interfere
with KIF21A dimerization. We hypothesize that the mutated
KIF21A is unable to carry its unidentified cargo from the
oculomotor nucleus motoneurons toward the developing neu-
romuscular junction of the extraocular muscle and that the
cargo is critical to the normal development of these axons.
Individuals with CFEOM2 (OMIM 602078) are born with
bilateral exotropic ophthalmoplegia and ptosis, with little phe-
notypic variability. We have identified this recessive disorder in
consanguineous pedigrees, mapped it to the FEOM2 locus on
11q13,9 and shown that it results from homozygous mutations
in PHOX2A (ARIX).10,11 PHOX2A encodes a homeodomain
transcription factor essential to the development of the oculo-
motor and trochlear motoneurons in mice and zebrafish.12,13
Hence, we propose that these cranial nuclei fail to form in
CFEOM2 probands.
Individuals with the third CFEOM phenotype, CFEOM3, are
those with CFEOM who do not have CFEOM1 or CFEOM2. This
includes, for example, individuals who have unilateral CFEOM,
have an orthotropic or hypertropic position in primary gaze, or
have a primary gaze that is hypotropic but can be elevated
above the midline in either eye. CFEOM3 can be inherited as an
autosomal dominant trait, and we have identified families in
which all affected individuals have CFEOM3,14,15 as well as
families in which some affected individuals have CFEOM3, and
some have CFEOM1.16 We define a CFEOM1 pedigree as a
CFEOM pedigree in which all affected individuals meet
CFEOM1 criteria and a CFEOM3 pedigree as one in which at
least ONE affected individual does not meet CFEOM1 criteria
(and the pedigree is not CFEOM2).5 CFEOM3 pedigrees typi-
cally demonstrate broader phenotypic variability than CFEOM1
and CFEOM2 pedigrees, and all contain at least one affected
family member with absent or unilateral ptosis, unilateral oph-
thalmoplegia, noninfraducted primary eye position, and/or the
ability to raise at least one globe above the horizontal midline.
We have described the linkage analyses of our three large
CFEOM3 pedigrees. The phenotype in two maps to a unique
locus, FEOM3, on 16qter14,16 (OMIM 600638), and the third
family’s phenotype maps back to the FEOM1 locus17
(CFEOM3A; OMIM 607034). The FEOM3 gene has not been
identified.
With the identification of KIF21A and PHOX2A as the
CFEOM1 and CFEOM2 disease genes, respectively, we are now
able to define our CFEOM3 population better. To elucidate the
genetic bases of CFEOM3, we identified the CFEOM3 cases in
our CCDD database, summarized their clinical phenotypes,
determined which CFEOM loci they potentially map to, and
screened each pedigree and sporadic case for mutations in
both KIF21A and PHOX2A.
METHODS
We identified all CFEOM3 index cases in our participant database using
the classification scheme just summarized.5 The study was approved
by the Children’s Hospital Boston institutional review board and in-
formed consent was obtained from participants and/or their guardians.
Our methods adhered to the Declaration of Helsinki for research
involving human subjects.
Each proband and his/her participating family members were ex-
amined and donated a blood sample. High-molecular-weight genomic
DNA was extracted from each blood sample according to standard
procedures. Linkage analysis using fluorescently labeled microsatellite
markers spanning the FEOM1, FEOM2, and FEOM3 loci was performed
on those pedigrees with sufficient structure.5 KIF21A mutation analy-
sis was conducted by PCR amplification of the 38 KIF21A exons and
flanking intron–exon boundaries from genomic DNA of each proband.
The amplicons were subjected to analysis by denaturing high-perfor-
mance liquid chromatography (DHPLC) using a nucleic acid fragment
analysis system (WAVE; Transgenomic, Inc., Omaha, NE) and/or to
direct DNA sequencing on an ABI 377 DNA sequencer (Applied Bio-
systems, Foster City, CA) as previously described.7 The PCR sequenc-
ing and DHPLC primers and conditions are available on request. The
three PHOX2A exons and flanking intron–exon boundaries were sim-
ilarly amplified using our published primer sets10 and these amplicons
were directly sequenced. Results were compared to normal control
individuals. If a mutation was detected in a proband, the participating
family members were subsequently screened for the mutation as well.
RESULTS
Phenotype
We identified 12 CFEOM3 pedigrees and 10 sporadic CFEOM3
individuals in our CCDD participant database that met our
inclusion criteria; their phenotypes are summarized in Table 1.
Of the 12 CFEOM3 pedigrees, at least 6 contained one or more
affected members with CFEOM1, and at least 3 contained one
or more affected members with unilateral ophthalmoplegia.
Although there was marked inter- and intrafamilial variability in
primary eye position and severity of vertical movement restric-
tion, hypotropic and exotropic globe positions were observed
more frequently than the hypertropic and esotropic positions.
Five of the 10 sporadic CFEOM3 individuals had unilateral
disease. Only two of those individuals had ptosis, and in each
case the ptosis was ipsilateral to the ophthalmoplegia. Among
the five individuals with bilateral ophthalmoplegia, four had
bilateral ptosis and one did not. At least two sporadic individ-
uals had an orthotropic primary gaze and one was hypertropic.
Most of the sporadic CFEOM3-bearing individuals had absent
or severely limited vertical gaze. In contrast, six had normal or
only mildly limited horizontal gaze.
Linkage and Haplotype Analysis
The family structures of 8 of the 12 CFEOM3 pedigrees permit
the generation of potentially meaningful haplotype data at the
FEOM1 and FEOM3 loci (Fig. 1 and Table 1). Of these, we have
published the clinical description and linkage analysis of the
data in pedigrees BN and DP, which map to the FEOM3
locus,14,16 and that in pedigree BW, which maps to FEOM1
with 97% penetrance and a maximum lod score of 10.8.17 Of
the 29 affected members of pedigree BW, 18 met CFEOM1
criteria and 11 met those for CFEOM3. The individuals with
CFEOM3 had absent ptosis, an orthotropic primary globe po-
sition, and/or residual upgaze. Of the five unpublished pedi-
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grees (BE, CS, AT, BF, and DR), haplotype analysis of BE is
consistent with linkage to FEOM1 and not to FEOM2 or
FEOM3. The six affected members of this family all have
bilateral ptosis and infraducted ophthalmoplegia, but are cate-
gorized as CFEOM3, because all can raise their eyes above the
midline, with  4% to 10% of the normal vertical excursion
(Fig. 2). Haplotype analysis of CS is consistent with linkage to
FEOM1 with reduced penetrance and FEOM3 with full pen-
etrance. The phenotypes of families AT, BF, and DR are not
linked to FEOM1 and are consistent with linkage to FEOM3.
The structures of the remaining four pedigrees (BI, BM, DC,
and FI) did not permit meaningful haplotype analysis (Fig. 1).
Analysis of the haplotype data for markers spanning the
FEOM2 locus reveals that only the phenotype of pedigree DR
was consistent with linkage to FEOM2, and this was as a
dominant disorder with reduced penetrance. In addition, none
of the sporadic individuals or affected members of the pedi-
grees reduced to homozygosity across the FEOM2 region.
Mutation Analysis
We screened 17 CFEOM3 probands for mutations in the
KIF21A gene, excluding the five pedigrees (BN, DP, AT, BF,
and DR) whose phenotypes did not map to FEOM1 and iden-
tified mutations in two of the CFEOM3 pedigrees. The affected
members of the Turkish pedigree BW, whose phenotype maps
to the FEOM1 locus,17 harbor a novel KIF21A heterozygous
2841G3A transition at the third nucleotide position of codon
947 in exon 20, resulting in a methionine-to-isoleucine substi-
tution (M947I; Fig. 3A). The affected members of the consan-
guineous Saudi Arabian pedigree BE, whose phenotype is con-
sistent with linkage to FEOM1 and none of the other loci,
harbor the most common CFEOM1 mutation,7 a heterozygous
2860C3T transition in exon 21, leading to an arginine-to-
tryptophan substitution (R954W; Fig. 3B). Each mutation seg-
regates with the CFEOM phenotype in each family and, as
predicted by haplotype analysis,17 the mutation was also
present in the clinically unaffected family member, BW-IV:2.
The 2841G3A change was not found on 210 normal control
alleles of diverse ethnicities, including 16 alleles in Turkish
pedigrees. The 2860C3T mutation has been reported in 32
CFEOM1 probands and established as a pathogenic missense
mutation.7 None of the remaining 15 probands harbors a
KIF21A mutation. Of note, a sporadic individual DB carried a
rare KIF21A single-nucleotide polymorphism, 3641C3G
(P1214R), that we identified earlier in two members of a large
CFEOM1 pedigree with the common 2860C3T mutation.7
To determine whether any cases of CFEOM3 result from
mutations in PHOX2A, we sequenced the three coding exons
in all probands, except for BW and BE who harbored KIF21A
mutations and BN and DP whose phenotypes mapped to
FEOM3. No PHOX2A mutations were detected.
DISCUSSION
We identified our cohort of CFEOM3 pedigrees and sporadic
individuals from our CCDD database and screened them for
linkage to the FEOM loci and for mutations in KIF21A and
PHOX2A. We identified pathogenic KIF21A missense muta-
tions in 2 (9%) of the 22 CFEOM3 probands in our database,
establishing that mutations in KIF21A are a rare cause of
CFEOM3 and confirming the genetic heterogeneity of
CFEOM3.
Pedigree BW is a large Turkish family whose CFEOM phe-
notype was strikingly different from the CFEOM1 pedigrees we
FIGURE 1. CFEOM3 pedigrees. Squares
and circles symbolize males and fe-
males, closed and open squares and
circles depict affected and unaffected
individuals, respectively, and a diago-
nal slash through a symbol denotes
that the individual is deceased. The
cross above and to the right of an
individual indicates participation in the
study. Pedigrees BN and DP mapped
to the FEOM3 locus, have been pub-
lished, and are not shown.14,16 Pedi-
gree BW has also been published.17
Note that pedigree BW had three con-
sanguineous loops and III:8 and III:19
represent the same individual.
FIGURE 2. Photographs of an af-
fected member of pedigree BE after
ptosis surgery with eyes in primary
position (center) and eight fields of
gaze. Note the participant’s ability to
raise both eyes slightly above the
midline. Her chin-up face position
improved significantly after correc-
tion of the ptosis. Similarly, other af-
fected family members’ chin-up posi-
tion also seemed to correlate best
with their degree of ptosis, suggest-
ing that their primary globe positions
were nearly neutral. Horizontal and
down gaze were relatively full.
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have described, yet the phenotype maps to the FEOM1 locus.17
Of interest, we found that the affected members of this pedi-
gree harbored a novel 2841G3A mutation in KIF21A that
alters the third nucleotide position of codon 947 (M947I). We
have previously identified CFEOM1 mutations at nucleotide
positions 1 and 2 of this codon.7 We found a heterozygous
2839A3G transition (M947V) at the first nucleotide position
in a small CFEOM1 pedigree with only three affected individ-
uals and a heterozygous de novo 2840T3G transversion
(M947R) at the second nucleotide position in an individual
with sporadic CFEOM1. Both the M947I and the M947V muta-
tions maintain nonpolar aliphatic R groups at codon 947 and
are the only disease-causing conservative KIF21A amino acid
substitutions we have identified. The M947I substitution is also
the first KIF21A mutation we have detected that results in
CFEOM with variable severity and incomplete penetrance. The
occurrence of a CFEOM3 rather than CFEOM1 phenotype in
pedigree BW may result in part from environmental factors and
genetic background. Of note, however, we have only identified
four CFEOM1 individuals with mutations at codon 947 (three
familial and one sporadic), and we know that a subset of
individuals within the CFEOM3 pedigree BW express the
CFEOM1 phenotype.17 Therefore, it is possible that mutations
in codon 947 or mutations that result in conservative amino
acid changes can cause a more variable and milder CFEOM
phenotype than KIF21A mutations at the other nucleotide
positions. Mutation studies of additional CFEOM pedigrees will
help to determine whether such phenotype–genotype predic-
tions are possible.
We identified a KIF21A mutation in only one additional
CFEOM3 pedigree, the Saudi Arabian pedigree BE. Of note, this
pedigree harbored the most common CFEOM1 “hotspot” mu-
tation, 2860C3T, found in 32 CFEOM1 families and sporadic
cases and accounting for 72% of all KIF21A mutation events we
have identified to date.7 In retrospect, we recognize that all six
affected members of pedigree BE shared a similar phenotype
that resembles CFEOM1 more closely than it resembles the
phenotypes found in the affected members of pedigree BW. All
six affected family members had bilateral infraducted ophthal-
moplegia and ptosis. Their degree of infraduction was small
compared with most CFEOM1 pedigrees, and they are classi-
fied as CFEOM3 because they could elevate their eyes slightly
above the midline. The ability to elevate their eyes could result
from a small degree of residual function of the superior rectus,
or possibly from the function of an aberrantly inserted superior
oblique or horizontal rectus muscle(s). Additional genetic stud-
ies to determine the frequency with which this common
KIF21A mutation occurs in CFEOM3 individuals, combined
with clinical studies documenting the degree of vertical excur-
sion in CFEOM1 individuals harboring KIF21A mutations,
should help determine whether it would be appropriate to
broaden our clinical definition of CFEOM1 to permit a small
degree of globe elevation above the horizontal. If this were
done, then pedigree BE and sporadic individual BR (in whom
we did not identify a KIF21A mutation) would be reclassified
as CFEOM1.
Combining these new findings with our published data, we
have now identified CFEOM1- and CFEOM3-causing mutations
in seven nucleotide positions at four distinct amino acid resi-
dues within three exons of KIF21A. The small number of
altered residues enhances the feasibility of cost-effective
KIF21A mutation detection in patients with CFEOM, despite
the large number of KIF21A exons. Currently, we screen
KIF21A exons 8, 20, and 21 before a more exhaustive search
of the remaining 35 exons.
None of the CFEOM3 pedigrees or sporadic cases had mu-
tations in the CFEOM2 gene, PHOX2A. This is similar to our
finding that none of our CFEOM1 cases harbored PHOX2A
FIGURE 3. Sequence chromatographs of unaffected control individuals (top) and individuals with CFEOM3 (bottom) showing heterozygous
mutations in KIF21A. (A) Members of pedigree BW harbored a novel transition, 2841G3A (M947I) (red triangle). Combined with the previously
reported mutations, indicated by black arrows beneath the chromatographs, we have now identified three different point mutations that alter
nucleotide positions 1, 2, and 3 of codon 947. (B) Members of pedigree BE harbor the common CFEOM1 mutation, 2860C3T (R954W) (red
triangle). Earlier, we identified the second most common CFEOM1 mutation, which alters nucleotide position 2 of codon 954, indicated by the
black arrow below the chromatograph.
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mutations,5 and reinforces CFEOM2 as the sole CFEOM phe-
notype caused by mutations in this gene.
We did not identify KIF21A or PHOX2A mutations in the
remaining 10 CFEOM3 pedigrees or in any of our sporadic
CFEOM3 individuals. Two of these CFEOM3 pedigrees were
linked to FEOM3, four were consistent with linkage to FEOM3,
and four were indeterminate. Therefore, we anticipate that
many of these pedigrees and a subset of the sporadic cases
harbor mutations in the unidentified FEOM3 gene.
Additional genetic studies, including the identification of
FEOM3 and other associated gene(s), will facilitate the molec-
ular genetic-based diagnosis of CFEOM phenotypes and will
help us to define better the CFEOM1 and CFEOM3 phenotypes
and to determine the feasibility of phenotype–genotype corre-
lations. In addition, future molecular investigations should lead
to a better understanding of the selective vulnerability of the
oculomotor and/or trochlear motoneuron unit by the muta-
tions in KIF21A, PHOX2A, and the unidentified FEOM3
gene(s).
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